<DOC>
	<DOCNO>NCT01674348</DOCNO>
	<brief_summary>It phase II , randomize , double-blind , placebo-controlled study P2202 patient type 2 diabetes mellitus , inadequately control stable dose metformin sulfonylurea .</brief_summary>
	<brief_title>A Clinical Trial Study Efficacy , Safety , Tolerability Pharmacokinetics P2202 Patients Type 2 Diabetes</brief_title>
	<detailed_description>It phase II , prospective , randomize , double-blind , placebo-controlled , dose-ranging , multi-centre , two-staged , fixed-design study P2202 patient type 2 diabetes mellitus , inadequately control stable dose metformin sulfonylurea . This study consist accrual Stage I ( n=56/arm , 70 % total sample size require ) , follow interim analysis completion treatment period , aid decision accrual dose selection Stage II study , completion Stage I .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Subjects understand willing give inform consent participate trial . Adult male female subject 18 year 65 year age BMI ≥ 27 kg/m2 ≤ 40 kg/m2 , inclusively . Subjects establish type 2 diabetes mellitus least 3 month duration time screen . Subjects inadequate glycemic control define HbA1c level ≥ 7.5 % ≥10 % screening . Subjects stable dose : Metformin ( 2.55 gm/day maximum tolerate dose least 1 gm/day ) and/or Sulfonylurea ( glimepiride ≤ 4 mg/day , gliclazide ≤ 160 mg , glibenclamide glyburide ≤ 10 mg glipizide ≤ 10 mg ) , ≤ 2 month prior screen visit . Subjects fast plasma glucose ≤14.4 mmol/L ( 260 mg/dL ) least 5.5 mmol/L 100 mg/dL . Subjects type 1 diabetes mellitus , maturityonset diabetes young rare form diabetes . Subjects hyperglycemia due secondary cause . Subjects 4 episode severe hypoglycemia 6 month prior screen . Subjects history acute diabetic complication Subjects treat insulin ( except use insulin short term management acute condition ) , thiazolidinediones , dual proliferator activate receptor agonist , glucagonlike peptide analogue , dipeptidyl peptidase inhibitor 11bHSD1 inhibitor form , 3 month prior screen . Subjects receive systemic glucocorticoid ( ≥14 day )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Diabetes Mellitus</keyword>
</DOC>